3篇
您的检索式：作者名="Giulia SOFIA"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 基于多尺度数字地形定量分析的月球线性构造自动提取研究显示文摘月球表面构造对于理解和重建月球地质构造演化具有重要意义,月岭、月溪等线性构造的形态及分布特征与月球内动力构造运动密切相关。极为有限的样品和难度极高的野外勘察使得遥感成为行星科学研究的最主要手段。中国、美国、日本、印度等国先后发射的多颗新型探月卫星获取了大量高质量数据,尤其是高分辨率的数字地形数据(DTM,Digital Terrain Model)。高分辨率的DTM为月球表面构造特征的自动提取带来了新的机遇与挑战。文中利用多种分辨率的DTM数据,基于多尺度数字地形定量分析方法,识别和提取月球表面的线性构造。使用的地形数据包括500m分辨率'嫦娥一号'激光高度计数据,100m分辨率LRO-WAC广角相机数据,60m分辨率的LRO-LOLA激光测距仪数据以及分辨率高达5m的LRO-NAC窄视角相机数据。文中使用地形曲率来识别月溪月岭等线性构造,并利用不同滑动窗口大小和阈值进行线性构造的自动提取。对研究区试验结果的定量分析表明,文中提出的基于地形曲率的月表线性构造自动提取方法是有效且可行的,其结果可为月球表面线性构造解译提供重要参考,提高构造解译时效性和精度。 | 李珂 陈建平 Paolo TAROLLI Giulia SOFIA 冯增文 李婧 | 2014 | 地学前缘2014，21，6： | 9 |
| 2 | Post-transplantation hepatocellular carcinoma recurrence: Patterns and relation between vascularity and differentiation degree显示文摘AIM: To evaluate the relationship between hepatocellular carcinoma(HCC) vascularity and grade; to describe patterns and vascular/histopathological variations of post-transplantation recurrence.METHODS: This retrospective study included 165 patients(143 men, 22 women; median age 56.8 years, range 28-70.4 years) transplanted for HCC who had a follow-up period longer than 2 mo. Pre-transplantation dynamic computed tomography or magnetic resonance examinations were retrospectively reviewed, classifying HCC imaging enhancement pattern into hypervascular and hypovascular based on presence of wash-in during arterial phase. All pathologic reports of the explanted livers were reviewed, collecting data about HCC differentiation degree. The association between imaging vascular pattern and pathological grade was estimated using the Fisher exact test. All follow-up clinical and imaging data were reviewed for evidence of recurrence. Recurrence rate was calculated and imaging features of recurrent tumor were collected, classifying early and late recurrences based on timing(< or ≥ 2 years after transplantation) and intrahepatic, extrahepatic and both intrahepatic and extrahepatic recurrences based onlocation. All intrahepatic recurrences were classified as hypervascular or hypovascular and the differentiation degree was collected where available. The presence of variations in imaging enhancement pattern and pathological grade between the primary tumor and the intrahepatic recurrence was evaluated and the association between imaging and histopatholgical variations was estimated by using the χ2 test. RESULTS: Of the 163 patients with imaging evidence of viable tumor, 156(95.7%) had hypervascular and 7(4.3%) hypovascular HCC. Among the 125 patients with evidence of viable tumor in the explanted liver, 19(15.2%) had grade 1, 56(44.8%) grade 2, 40(32%) grade 3 and 4(3.2%) grade 4 HCC, while the differentiation degree was not assessable for 6 patients(4.8%). A significant association was found between imaging vascularity and pathological grade(P = 0.035). Post-transplantation recurrence rate was 14.55%(24/165). All recurrences occurred in patients who had a hypervascular primary tumor. Three patients(12.5%) experienced late recurrence; the location of the first recurrence was extrahepatic in 14 patients(58.3%), intrahepatic in 7 patients(29.2%) and both intrahepatic and extrahepatic in 3 patients(12.5%). Two patients had a variation in imaging characteristics between the primary HCC(hypervascular) and the intrahepatic recurrent HCC(hypovascular), while 1 patient had a variation of histopathological characteristics(from moderate to poor differentiation), however no association was found between imaging and histopathological variations.CONCLUSION: A correlation was found between HCC grade and vascularity; some degree of variability may exist between the primary and the recurrence imaging/histopathological characteristics, apparently not correlated. | Annarita Pecchi Giulia Besutti Mario De Santis Cinzia Del Giovane Sofia Nosseir Giuseppe Tarantino Fabrizio Di Benedetto Pietro Torricelli | 2015 | World Journal of Hepatology2015，7，2： | 5 |
| 3 | Pharmacogenetics of thiopurines显示文摘Polychemotherapeutic protocols for the treatment of pediatric acute lymphoblastic leukemia(ALL)always include thiopurines.Specific approaches vary in terms of drugs,dosages and combinations.Such therapeutic schemes,including risk-adapted intensity,have been extremely successful for children with ALL who have reached an outstanding 5-year survival of greater than 90%in developed countries.Innovative drugs such as the proteasome inhibitor bortezomib and the bi-specific T cell engager blinatumomab are available to further improve therapeutic outcomes.Nevertheless,daily oral thiopurines remain the backbone maintenance or continuation therapy.Pharmacogenetics allows the personalization of thiopurine therapy in pediatric ALL and clinical guidelines to tailor therapy on the basis of genetic variants in TPMT and NUDT15 genes are already available.Other genes of interest,such as ITPA and PACSIN2,have been implicated in interindividual variability in thiopurines efficacy and adverse effects and need additional research to be implemented in clinical protocols.In this review we will discuss current literature and clinical guidelines available to implement pharmacogenetics for tailoring therapy with thiopurines in pediatric ALL. | Raffaella Franca Giulia Zudeh Sofia Pagarin Marco Rabusin Marianna Lucafò Gabriele Stocco Giuliana Decorti | 2019 | Cancer Drug Resistance2019，2，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员